Health care stocks were softer late Tuesday afternoon, with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund (XLV) each easing 0.2%.
The iShares Biotechnology ETF (IBB) shed 0.6%.
In corporate news, Chimerix (CMRX) shares soared 224% a day after the company said it plans to submit a new drug application with the US Food and Drug Administration seeking accelerated approval for dordaviprone.
UniQure (QURE) shares surged 110% after Wells Fargo upgraded the company's stock to overweight from equalweight, with a $35 price target. The upgrade follows the company's announcement that it reached an agreement with the US Food and Drug Administration on elements of an accelerated approval pathway for its drug AMT-130, a potential treatment for Huntington's disease.
Walgreens Boots Alliance (WBA) shares surged 16%. The company is in talks to be acquired by private equity firm Sycamore Partners, The Wall Street Journal reported, citing people familiar with the matter.
CervoMed (CRVO) shares plunged 78% after the company said a phase 2b trial assessing neflamapimod to treat people with dementia with Lewy bodies failed to meet its primary or key secondary endpoints.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。